Geneticure is a Mayo Clinic-backed pharmacogenomics (PGx) company leveraging genetic information to identify which anti-hypertension treatment is most likely to work for each patient based on their DNA. Geneticure takes a unique approach in PGx with its peer-reviewed clinical and health economic evidence and focuses on the genetics of integrative-physiology in chronic disease. Using a cheek swab, Geneticure recommends which hypertension medication(s) may give you the biggest drop in blood pressure. Geneticure’s test looks at 17 genotypes and 11 genes* to determine how your body responds to each medication. The Geneticure approach of DNA-guided therapy is associated with ~7mmHg lower systolic blood pressure and ~6mmHg diastolic blood pressure. This is 22% and 39% lower respectively versus non-genetically matched care.